Moderna delays Phase 3 trial for COVID-19 vaccine
Moderna’s heavily anticipated trial for a coronavirus vaccine, which was set to begin next week, has been delayed.“Moderna has previously disclosed that the Phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 is expected to begin in July. The trial is still expected to begin in July and we expect to be the first to start a Phase 3 trial,” read a company statement sent to The New York Daily News Thursday. “We have worked closely with NIH/OWS to align on the final protocol in order to begin the trial on time.”The Phase 3 study, which includes 30,000 patients, was initially supposed to begi...
New York Daily News
Anti-malaria drug hydroxychloroquine does little to prevent COVID-19, trial finds
An anti-malaria drug that has been trumpeted as a therapy for COVID-19 was unable in a University of Minnesota clinical trial to prevent the onset of the infectious disease.The results of the nation’s first randomized trial with the drug, hydroxychloroquine, against COVID-19 will disappoint doctors who had hoped for new therapies against the pandemic. Many prescribers had given it off-label to COVID-19 patients — in the absence of other options — and President Donald Trump had been an early champion of the drug and disclosed in mid-May that he was taking it for the preventive benefit that the ...
Star Tribune (Minneapolis)